TokenPost·
Rapport Therapeutics' RAP-219 Meets Phase 2 Goals in Bipolar Mania Trial
3.1-point
mania scale advantage
RAP-219 showed a 3.1-point advantage on a mania rating scale after three weeks, but 24.6% of recipients stopped treatment early.
More news
- TokenPostMeta Pauses Muse Sharing After More Than 6,800 Shared-Chat Hostnames Surface
- TokenPostFrance Advances Proposed 31.4% Tax on Crypto-to-Stablecoin Gains
- TokenPostLiquid Restores Bitcoin Swaps While Direct Peg-Outs Remain Frozen
- Crypto BriefingMusk projects at least 13 gigawatts of AI compute by end of next year
- TokenPostAugnition US Fund Files SEC Notice for Delaware Hedge Fund Offering
- TokenPostCircle-Linked Stock Tokens Use Different Structures and Trading Terms